Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
Assessed by RV013 · Clinical Chair in Health Services Research
Assessed on 16 Nov 2025
OverallReviewer's overall integrity assessment, derived from all research questions Some concerns
DOI 10.1136/bmj-2025-084290 (opens in new tab)
Resource ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233
5 Research Questions · 85 Evidence Items
Q1.1 — Does the study have an associated retraction?
Rationale: Agree, no notice on website.
Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?
Rationale: Agree, no notice on BMJ. Interesting rapid response though.
Q1.3 — Do other studies by the research team highlight causes for concern?
Rationale: Given numbers of names matching RW's database, even if names are very similar, this is a concern and institutions need to be checked too
Supporting Evidence (83)
Retraction NoticeSource: Retraction Watch database
Dynamics Simulation Efficiency of the Chain-drive Mechanism
10.1109/cmce.2010.5609860 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 10652
Rationale: Notice - Limited or No Information
About Author: Qiang Liu
Retraction NoticeSource: Retraction Watch database
Banking opening up, introducing foreign strategic investors and the innovation ability of China's Banks
10.1109/fitme.2010.5654808 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 12393
Rationale: Investigation by Journal/Publisher;Notice - Limited or No Information;Removed
About Author: Yingying Zhu
Retraction NoticeSource: Retraction Watch database
LCK: a new biomarker candidate for the early diagnosis of acute myocardial infarction
10.1007/s11033-015-3907-5 (opens in new tab)RetractionWatch ID:Record identifier in the Retraction Watch database 1367
Rationale: Fake Peer Review;Investigation by Journal/Publisher
About Author: Fei Xu
Q2.2 — Are there concerns relating to the timing or absence of study registration?
Rationale: Prospective registration, just.
Supporting Evidence (2)
Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)
Registration ID: NCT05165069
Registry: ClinicalTrials.gov
Registry Link: https://clinicaltrials.gov/study/NCT05165069 (opens in new tab)
Registration Date: 20-12-2021
Prospective:Whether the trial was registered before participant recruitment began Yes
Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates Comparison performed at month level. Registration: 2021-12, LLM Recruitment Start: 2022-01. Deemed prospective at month level.
Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text
Recruitment Start: 01-2022
Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date Setting: 'Seven hospitals in China between January 2022 and February 2024'; no specific day found.
Recruitment End: 02-2024
Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date Setting: 'Seven hospitals in China between January 2022 and February 2024'; no specific day found.
Study End: N/A
Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date No explicit study completion date found.
Overall — What is the overall integrity assessment of the study?
Rationale: Authorship issues need further evaluation.